Showing 1,431 - 1,437 of 1,437
A variety of methods are available to measure preferences for temporary health states for cost-utility analyses. The objectives of this review were to summarize the available temporary health-state valuation methods, identify advantages and disadvantages of each, and identify areas for future...
Persistent link: https://www.econbiz.de/10005041936
This paper reviews the role of patient preferences within the framework of cost-effectiveness analysis (CEA). CEA typically adopts a system-wide perspective by focusing upon efficiency across groups in the allocation of scarce healthcare resources, whereas treatment decisions are made over...
Persistent link: https://www.econbiz.de/10005041937
Background: Within the framework of economic evaluations, the transferability of utility scores between jurisdictions remains unclear. The EQ-5D is a generic instrument for measuring health-related quality of life in economic evaluations, which can be used for comparing utility scores across...
Persistent link: https://www.econbiz.de/10005041938
Background: Various software packages are commonly used for the implementation and calculation of decision-analytic models for health economic evaluations. However, comparison of these programs with regard to ease of implementing a model is lacking. Objectives: (i) to compare the assets and...
Persistent link: https://www.econbiz.de/10005041939
Background: There is a lack of a uniform proxy for defining direct medical costs in the US. This potentially important source of variation in modelling and other types of economic studies is often overlooked. The extent to which increased expenditures for an intervention can be offset by...
Persistent link: https://www.econbiz.de/10005041940
Background: Nearly 1 million new episodes of herpes zoster (HZ) occur annually in the US, yet little is known about the medical resource utilization (RU) and costs associated with HZ and its complications. Objective: To describe the medical RU and cost burden of HZ in the first 90 days and the...
Persistent link: https://www.econbiz.de/10005041941
Background: The erythropoiesis-stimulating agents (ESAs) epoetin alfa (EA) and darbepoetin alfa (DA) have comparable efficacy in treating chemotherapy-induced anaemia (CIA). Therapy choice depends on many factors, including cost. Previous estimates of ESA cost differences have been derived from...
Persistent link: https://www.econbiz.de/10005041942